Overview Efficacy and Safety of IVIG-L in ITP Patients Status: Completed Trial end date: 2002-03-01 Target enrollment: Participant gender: Summary The efficacy and safety of a liquid intravenous immunoglobulin product, IVIG-L, in patients with ITP will be assessed and compared with data obtained from literature. Phase: Phase 3 Details Lead Sponsor: SanquinSanquin Plasma Products BVTreatments: AntibodiesImmunoglobulins